Botulinum Toxin A Versus Myricetin for Enhancing Random-Pattern Flap Survival: A Comparative Experimental Study

Area of Science:

• Regenerative Medicine
• Vascular Surgery
• Pharmacology

Background:

• Ischemia-related complications are a major challenge in flap surgeries, increasing morbidity.
• Myricetin, a flavonoid, has known antioxidant and anti-inflammatory properties but its effect on flap survival is unknown.
• This study investigates myricetin and botulinum toxin A (BTX-A) for improving flap survival.

Purpose of the Study:

• To compare the efficacy of botulinum toxin A (BTX-A) and myricetin, individually and in combination, in enhancing flap survival.
• To evaluate the impact of these agents on tissue oxygenation, inflammation, and oxidative stress in a rat flap model.

Main Methods:

• A rat model with a modified McFarlane flap was used, with 40 rats divided into five groups.
• Treatments included control, BTX-A, myricetin, and combination therapy.
• Flap survival, vascularity, inflammation, and biochemical markers of oxidative stress were assessed.

Main Results:

• Both BTX-A and myricetin significantly increased flap survival rates compared to the control group (P<0.001).
• Combination therapy demonstrated the highest flap survival rate (13.56%).
• Histopathology showed increased vascular density and reduced inflammation; biochemical analysis indicated improved antioxidant status.

Conclusions:

• BTX-A and myricetin significantly improve flap survival in a rat model.
• Combination therapy offers the most benefit, reducing necrosis and enhancing flap viability.
• These agents show promise in improving outcomes for patients undergoing flap surgery by enhancing oxygenation and modulating inflammation.